Structured evidence table for Barley Beta Glucan Gut Health Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Barley Beta Glucan Gut Health Randomized Trial | Coronary artery disease, stroke, insulin resistance, type 2 diabetes, hypertension, and metabolic syndrome are well-known medical comorbidities associated with excess body weight []. | 3 | El Khoury D. (2012) | Beta Glucan: Health Benefits in Obesity and Metabolic Syndrome |
| Barley Beta Glucan Gut Health Randomized Trial | It is directly associated with increased risk of type 2 diabetes and cardiovascular diseases. | 3 | El Khoury D. (2012) | Beta Glucan: Health Benefits in Obesity and Metabolic Syndrome |
| Barley Beta Glucan Gut Health Randomized Trial | Although the ideal dietary pattern for patients with metabolic syndrome has not been defined, there is growing evidence that high intakes of fruits, vegetables, legumes, and cereals are beneficial [–]. | 3 | El Khoury D. (2012) | Beta Glucan: Health Benefits in Obesity and Metabolic Syndrome |
| Barley Beta Glucan Gut Health Randomized Trial | 1 2 3 Obesity has reached global epidemic proportions with more than one billion adults affected by this chronic disorder []. | 3 | El Khoury D. (2012) | Beta Glucan: Health Benefits in Obesity and Metabolic Syndrome |
Source documents